Rheumatoid Arthritis Market is expected to increase from $56.6 billio Rheumatoid Arthritis Market 2020

Rheumatoid Arthritis Market is expected to increase from $56.6
billion in 2013 to $80.7 billion in 2020: Radiant Insights, Inc
Summary
Increasingly Crowded Market for Second-Line Therapies Improving Treatment Options for Moderate-toSevere Rheumatoid Arthritis Patients
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that
primarily affects joints. It is characterized by synovial inflammation and gradual bone erosion over many
years, and disease progression results in stiffness and pain, especially in the hands and feet, which hinders
patient mobility. Without treatment, the disease leads to joint destruction and disability. Prior to 1998,
treatment options were limited to small-molecule disease-modifying therapies, such as Methotrexate
(MTX), sulfasalazine and anti-malarials. However, while MTX is efficacious in controlling RA
symptoms in a large percentage of patients, approximately 33% are unresponsive to these first-line drugs.
The approval of revolutionary biological therapies, including Enbrel, Remicade and Humira, for the
treatment of RA patients that are refractory to MTX has triggered unparalleled growth in the market.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/rheumatoidarthritis-market-to-2020-a-crowded-market-characterized-by-modest-growth
Globally, there are at least 12 biological therapies, including monoclonal antibodies (mAb), biosimilars
and therapeutic proteins, competing as second-line therapies for this sub-population. Over the past 16
years, the therapeutic market for RA has become extremely competitive as a result of the high number of
new drug approvals. Competition for Tumor Necrosis Factor Alpha (TNF-a) inhibitors is particularly
fierce, and now dominates the treatment market for RA patients who are refractory to first-line Disease
Modifying Anti-Rheumatic Drugs (DMARD). In 2013, three TNF-a targeting mAbs, Humira
(adalimumab), Remicade (infliximab) and Enbrel (etanercept), were ranked among the top-10 best-selling
drugs in the world, with global revenues of $11.1 billion, $9.9 billion and $8.9 billion respectively,
reflecting their groundbreaking clinical and commercial success. Despite this, 30% of RA patients fail to
achieve clinical responses when treated with TNF-a inhibitors (Rubbert-Roth and Finckh, 2009).
However, patients who are unresponsive to TNF-a inhibitors can also be medicated with the cytokine
modulators Rituxan and Xeljanz. Thus, the extensive range of available therapies is addressing the need
for efficacious therapies for a broad spectrum of RA patients.
Modest Rate of Market Growth Expected between 2013 and 2020
The market for disease-modifying RA therapeutics is expected to increase from $56.6 billion in 2013 to
$80.7 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 5.2%. First-line DMARDs are
expected to remain stagnant, as the late-stage pipeline predominantly constitutes second-line therapies.
The high number of clinically and commercially strong products in the current market represents a barrier
for the market infiltration of such emerging therapies. In the EU market, the patent expiration of
blockbuster drugs from 2015 is expected to cause a strong uptake of biosimilars. However, uncertainty